Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Arjil Pharmaceuticals LLC

Clinicaltrial registered3 Nov 2026

Arjil Pharmaceuticals LLC

3 Nov 2026: Trial registered · A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
3 Nov 2026
Title
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis
Conditions
Dermatitis Atopic
Phase
Phase 2
Study Type
Interventional
Status
Recruiting
Countries
Taiwan
Country
Taiwan
Reference
NCT07914088
Location
Taiwan
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Arjil Pharmaceuticals LLC

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Taiwan

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.